I have heard many people comment about the insurance policies for cars, houses, life, assets, etc. The arguments always revolve around the same issue: Is it really necessary? What are the chances to be hit by a Hurricane, or to meet a sudden death? Well, nobody really knows. Some individuals however, sleep better when they know a policy backs their life investments. Here, I will look into three insurance companies that concentrate on different policies, or geographies. These are: China Life (LFC), and Conseco (CNO).
Insuring China
Based in Beijing, China Life is the leading individual life insurance provider. Additionally, the firm provides group life insurance, accident and health insurance, and annuity products throughout mainland China. Most recently, the Chinese government has loosened the grip on insurance interest rates, opening the way to new profitable opportunities.
China Life short-term outlook is promising given a strong brand name, wide domestic network, stable ratings, and aggressive investments. Such characteristics have granted the company safeguards to counter stronger domestic competition, and bolster top line growth. Holding the largest customer base and distribution network, coupled with a dedicated customer service have raised the quality in service, keeping competition at a distance.
Top Retail Companies To Own In Right Now: Telecom Italia S.P.A.(TI)
Telecom Italia S.p.A., together with its subsidiaries, provides fixed-line and mobile telecommunications, Internet, and media services. The company also operates in office and system solutions. Its portfolio ranges from consumer-focused convergent communications services to business-oriented advanced ICT solutions. The company?s integrated range of offerings, proprietary platforms, and network architecture leverage the potential of fixed-line and mobile broadband to offer convergent solutions for communication, Web surfing, always-in-touch services, and serve as a gateway to the digital world from the home, the office, and on the move, from fixed-line telephone, cell phone, PC, or TV. Its business portfolio covers various categories of business needs, from freelance professionals to SMEs, corporations, institutions, and public government bodies. The company?s Web offerings combine Italy?s Virgilio portal with Web 2.0 ventures, such as Yalp!, a TV community where users p ublish their own content and create their own TV channels. Its media operations span traditional broadcasting over analogue and digital networks, and mobile broadcasting through TIM/MTV partnership vehicle, MTV Mobile. The company has operations in Italy, Latin America, Germany, Holland, and the Mediterranean basin. As of December 31, 2009, it provided fixed telecommunications services with approximately 16.1 million physical accesses in Italy. The company?s wholesale customer portfolio consisted of approximately 6.2 million accesses for telephone services; and broadband portfolio had approximately 8.7 million accesses in Italy, as well as 30.8 million mobile telephone lines. Telecom Italia was founded in 1908 and is headquartered in Milan, Italy.
Advisors' Opinion:- [By Jon C. Ogg]
Telecom Italia SpA (NYSE: TI) was raised to Neutral from Underperform at J.P. Morgan.
Xilinx Inc. (NASDAQ: XLNX) was raised to Outperform from Sector Perform with a $55 price target (versus $a 46.54 close) at Pacific Crest.
- [By Sean Williams]
Don't forget the cash flow
With austerity measures hitting home in Europe, it's fairly easy to understand why Telecom Italia (NYSE: TI ) (NYSE: TI-A ) , Italy's largest telephone service provider, has struggled mightily. Unlike in the U.S., where a landline or cell phone are viewed as practical necessities, consumers in Italy have had no problem giving up their landlines, or businesses postponing their network expansion, until Italy's economy improves. In fact, in Telecom Italia's first-quarter report, we saw EBITDA decline 10%, to $3.5 billion, and overall sales dip 8%. - [By DAILYFINANCE]
Brent Lewin/Bloomberg via Getty Images NEW YORK -- Facebook (FB) is placing a $19 billion bet on reaching its next billion mobile users with the acquisition of WhatsApp, a popular messaging service that lets people send texts, photos and videos on their smartphones. The $19 billion deal is by far Facebook's largest and bigger than any that Google (GOOG), Microsoft (MSFT) or Apple (AAPL) have ever done. But it is likely to raise worries that Facebook and other technology companies are starting to become overzealous in their pursuit of promising new products and services, said Anthony Michael Sabino, a St. John's University business professor. "This could be seen as a microcosm of a bubble," Sabino said. "I expect there to be a lot of skepticism about this deal. People are going to look at this and say, 'Uh-oh, did they pay way too much for this?" Facebook, for its part, is taking the long view. WhatsApp has 450 million monthly users, 70 percent of whom use it every day. The service is adding a million new users a day. There are 19 billion messages sent and 34 billion received via WhatsApp each day, in addition to 600 million photos and 100 million video messages. At this rate, Facebook CEO Mark Zuckerberg is confident the app will reach a billion users. Services that reach that milestone, Zuckerberg said in a statement, "are all incredibly valuable." It's an elite group to be sure -- one that includes Google (which owns YouTube), Facebook itself and little else. Facebook said Wednesday that it's paying $12 billion in stock and $4 billion in cash for WhatsApp. In addition, the app's founders and employees -- 55 in all -- will be granted restricted stock worth $3 billion that will vest over four years after the deal closes. The transaction translates to roughly 11 percent of Facebook's market value. In comparison, Google's biggest deal was its $12.5 billion purchase of Motorola Mobility, while Microsoft's largest was Skype at $8.5 billion. Apple, meanwhil
- [By DAILYFINANCE]
Steven Senne/AP NEW YORK -- Target (TGT) massive data breach over the holidays helped push its fourth-quarter profit down 46 percent. The discount retailer also said Wednesday that sales fell 5.3 percent as the breach scared off customers. The nation's second-largest discounter also offered a profit outlook below Wall Street expectations as the costs of the breach that affected millions of credit and debit card customers linger. The discounter, based in Minneapolis, said it earned $520 million, or 81 cents a share, for the three months that ended Feb. 1. That compares with a profit of $961 million, or $1.47 a share a year earlier. Revenue fell to $21.5 billion from $22.7 billion. Revenue at stores open at least a year, an important retail measurement, fell 2.5 percent. Analysts had expected a profit of 80 cents on revenue of 21.5 billion, according to FactSet estimates. The breach resulted in $17 million of net expenses in the fourth quarter, Target said, with $61 million of total expenses partially offset by the recognition of a $44 million insurance receivable. Shares of Target rose 99 cents to $57.50 in premarket trading Wednesday as earnings results beat Wall Street estimates by a penny. The stock has fallen about 10 percent since the company disclosed the breach in mid-December. "As we plan for the new fiscal year, we will continue to work tirelessly to win back the confidence of our guests. We are encouraged that sales trends have improved in recent weeks," Gregg Steinhafel, chairman, president and CEO of Target, said in a statement. The results underscore the big challenges that Steinhafel faces. Even before the breach, Target has struggled with uneven sales since the recession as its middle-income shoppers are still not comfortable in spending. And the company has also grappled with the perception that its prices are too high. Critics also say that the discounter, known for its exclusive limited partnerships with designers, has lost its
5 Best Promising Stocks To Watch For 2014: Golden Valley Bank (GVYB)
Golden Valley Bank is owned and operated commercial bank serving the needs of individuals and businesses in northern California. The Bank provides personal services, such as checking and savings and IRAs. The Bank�� business includes checking, savings, commercial lending, online banking and eDeposit.
The Bank provides business owners; commercial developers and investors, and residential builders and developers. Golden Valley Bank's business online banking service provides account management, bill pay and transactions services.
Advisors' Opinion:- [By CRWE]
Today, GVYB remains (0.00%) +0.000 at $9.00 thus far (ref. google finance Delayed: 11:59AM EDT July 17, 2013).
Golden Valley Bank headquartered in Chico, California previously reported June 30, 2013 financials. The company also announced their $.05 per share second quarter cash dividend.
2nd Quarter 2013 Financial Highlights: Year to date net profit $683,911 compared to $514,030 year to date in 2012; Assets up $14.9 million to $136.7 million, or 12.2%, over the second quarter of 2012; Loans up $6.2 million to $89.5 million, or 7.4%, over the second quarter of 2012; Deposits up $14.6 million to $118.6 million, or 14%, over the second quarter of 2012
The results of the Gravity Survey will be released once they are available
5 Best Promising Stocks To Watch For 2014: TCF Financial Corporation(TCB)
TCF Financial Corporation operates as the bank holding company for TCF National Bank that provides various retail and commercial banking products and services in the United States and Canada. Its products and services include consumer, small business, and commercial deposits, as well as interest-bearing checking accounts, money market accounts, regular savings accounts, certificates of deposit, and retirement savings plans; and consumer real estate loans, commercial real estate loans, commercial business loans, and multi-purpose campus cards for colleges, as well as consumer loans for personal, family, or household purposes. The company also offers leasing and equipment finance products for various companies, inventory finance products, auto finance products, and treasury services. As of December 31, 2011, it had 434 retail banking branches, including 196 branches in Illinois, 110 in Minnesota, 53 in Michigan, 36 in Colorado, 26 in Wisconsin, 7 in Arizona, 5 in Indiana, an d 1 in South Dakota. The company was founded in 1923 and is based in Wayzata, Minnesota.
Advisors' Opinion:- [By Tim Melvin]
I always find it very interesting to see what long-term investors are selling in a given quarter. Kahn Brothers lightened up on many financials that have shot up and now trade above book value. The firm sold out of Flushing Financial (FFIC), TCF Financial (TCB) and Dime Community Bank (DCOM). Khan apparently shares my views on the large-cap drug stocks, easing up on both Pfizer (PFE) and Bristol Meyers (BMY) over the summer. Khan Brothers also sold the last of the Travelers shares (TRV) it has owned since 2008 at more than twice the purchase price.
- [By Zacks]
Shares of TCF Financial Corporation (NYSE: TCB) have recorded a year-to-date return of 26.6%. Impressive organic growth, balance sheet repositioning and strong capital deployment activities of the company were primary factors behind the growth. However, we are not so optimistic about these positives translating into further price appreciation down the road as there will likely be significant pressure on its top line.
5 Best Promising Stocks To Watch For 2014: StemCells Inc (STEM)
StemCells, Inc. (StemCells), incorporated in August 1988, is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�� primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�� human liver cells as a therapeutic product.
CNS Program
The Company in its CNS Program, is in clinical development with its HuCNS-SC cells for a range of disorders of the central nervous system. The CNS includes the brain, spinal cord and eye. In February 2012, the Company had completed a Phase I clinical trial in Pelizeaus-Merzbacher Disease (PMD), a fatal myelination disorder in the brain.
The Company�� CNS Program is focused on developing clinical applications, in which transplanting HuCNS-SC cells protect or restore organ function of the patient before such function is irreversibly damaged or lost due to disease progression. The Company�� initial target indications are PMD, and more generally, diseases in which deficient myelination plays a central role, such as cerebral palsy or multiple sclerosis; spinal cord injury, disorders in which retinal degeneration plays a central role, such as age-related macular degeneration or retinitis pigmentosa. The Company�� product candidate, HuCNS-SC cells, is a purified and expanded composition of normal human neural stem cells. Its HuCNS-SC cells can be directly transp! lanted.
Liver Program
Liver stem or progenitor cells offer an alternative treatment for liver diseases. A liver cellular therapy or cell-based therapeutic provide or support liver function in patients with liver disease. The Company held a portfolio of issued and allowed patents in the liver field, which cover the isolation and use of both hLEC cells and the isolated subset, as well as the composition of the cells themselves.
The Company�� range of cell culture products, which are sold under the SC Proven brand, includes iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff N2, and NDiff N2B27. Its iSTEM is a serum-free, feeder-free medium that maintains mouse embryonic stem cells in their pluripotent ground state by using selective small molecule inhibitors to block the pathways, which induce differentiation. RHB-A is a defined, serum-free culture medium for the selective culture of human and mouse neural stem cells and their maintenance and expansion as adherent cell populations. RHB-Basal is a defined, serum-free basal medium. When supplemented with specific growth factors, this media is formulated for the propagation and differentiation of adherent neural stem cells. RHB-Basal can also be tailored to specific-cell type requirements by the addition of customer preferred supplements.
The Company�� NDiff N2 is a defined serum-free scell culture supplement for the derivation, maintenance, expansion and/or differentiation of human and mouse embryonic stem (ES) cells and tissue-derived neural stem cells supplement. Its NDiff N2-AF is a serum-free and animal component-free version of NDiff N2. Its NDiff N2B27 is a defined, serum-free medium for the differentiation of mouse embryonic stem cells to neural cell types. NDiff N27-AF is a serum-free and animal component-free version of NDiff N27. Its GS1-R is a serum-free media formulation shown to enable the derivation and long-term maintenance of true, germline competent rat embryonic stem cells without the add! ition of ! cytokines or growth factors. Its GS2-M is a defined, serum- and feeder-free medium for the derivation and long-term maintenance of true, germline competent mouse iPS cells.
The Company also markets a number of antibody reagents for use in cell detection, isolation and characterization. These reagents are also under the SC Proven brand and it includes STEM24, STEM101, STEM121 and STEM123. Its STEM24 is a human antibody that recognizes human CD24, also known as heat stable antigen (HSA), a glycoprotein expressed on the surface of many human cell types, including immature human hematopoietic cells, peripheral blood lymphocytes, erythrocytes and many human carcinomas. Its CD24 is also a marker of human neural differentiation. Its STEM101 is a human-specific mouse antibody that recognizes the Ku80 protein found in human nuclei. Its STEM121 is a human-specific mouse antibody that recognizes a cytoplasmic protein of human cells. Its STEM123 is a human-specific mouse antibody that recognizes human glial fibrillary acidic protein (GFAP).
The Company�� Other products marketed under SC Proven include total cell genomic DNA (gDNA), RNA and protein lysate reagents purified from homogenous stem cell populations for intra-comparative studies, such as Epigenetic fingerprinting, Southern, Western and Northern blots, PCR, RT-PCR and microarrays. This range of purified stem cell line lysates includes mouse embryonic stem (ES) cells propagated in SC Proven 2i inhibitor-based GS2-M media and mouse ES cell-derived and fetal tissue-derived neural stem (NS) cells propagated in SC Proven RHB-A media.
Advisors' Opinion:- [By James E. Brumley]
When an investor thinks of spinal-related stem cell stocks, usually a name like Neuralstem, Inc (NYSEMKT: CUR) or StemCells Inc (NASDAQ: STEM) comes to mind. And well they should. STEM has logged some amazing breakthroughs in the field of spinal cord repair, while CUR has done the same. Not all back problems are spinal cord related though. In fact, most back problems - and therefore the most opportunity - are bone and disc related problems. That's where a young gun like BioRestorative Therapies (OTCBB: BRTX) can step in and make stem cell waves. BRTX has developed an approach to rejuvenate and revive failing spinal discs, potentially ending pain for millions of back-pain sufferers, and circumventing expensive spinal surgeries that are in increasing burden on insurance companies.
- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
- [By Garrett Cook]
Healthcare shares gained 0.81 percent in the US market on Friday. Top gainers in the sector included Shire plc (NASDAQ: SHPG), StemCells (NASDAQ: STEM), and Flamel Technologies SA (NASDAQ: FLML).
No comments:
Post a Comment